Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
Mengke Niu, Yiming Liu, Ming Yi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 93

Showing 26-50 of 93 citing articles:

Prognostic significance of soluble PD-L1 in prostate cancer
Margarita Zvirble, Žilvinas Survila, Paulius Bosas, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Illuminating the impact of CD38-induced adenosine formation in B-cell lymphoma
Shams ElDoha Galal ElDin Zaiema, Heba Mohamed Saber Hafez, Diaa El-Din Moussa Sherif Abou El-Ela, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Association between clinical activity score and serum sPD-1 and sPD-L1 levels during systemic glucocorticoid treatment for active moderate-to-severe thyroid eye disease
Katarzyna Cieplińska, Emilia Niedziela, Agata Kopacz Rdzanek, et al.
Cytokine (2025) Vol. 187, pp. 156862-156862
Closed Access
Colorimetric aptasensor coupled with a deep-learning-powered smartphone app for programmed death ligand-1 expressing extracellular vesicles
Adeel Khan, Haroon Latif Khan, Nongyue He, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Soluble PD-L1 and Serum Vascular Endothelial Growth Factor-B May Independently Predict Prognosis in Patients with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab
Eleni Kokkotou, Dimitra Grapsa, Anna Papadopoulou, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 421-421
Open Access
Engineered oncolytic virus coated with anti-PD-1 and alendronate for ameliorating intratumoral T cell hypofunction
Yufu Zhu, Xuefeng Zhang, Jiaqi Jin, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Current Biomarkers in Non-Small Cell Lung Cancer—The Molecular Pathologist’s Perspective
Konrad Steinestel, Annette Arndt
Diagnostics (2025) Vol. 15, Iss. 5, pp. 631-631
Open Access
Amuc_1434 From Akkermansia muciniphila Enhances CD8+ T Cell‐Mediated Anti‐Tumor Immunity by Suppressing PD‐L1 in Colorectal Cancer
Jiahao Zhu, Shaolei Qin, Ruike Gu, et al.
The FASEB Journal (2025) Vol. 39, Iss. 8
Closed Access
Exosome-based immunotherapy in hepatocellular carcinoma
Zhihong Liu, Guowei Wang, Zhi Li, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access
Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics
Michael Macklin, Sudeep Pradeep Yadav, Reem Jan, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 259-259
Open Access | Times Cited: 10
sPD-L1 and sPD-L2 in plasma of patients with lung cancer and their clinical significance
Shiyang Han, Yan Zhang, Jingzhi Yuan, et al.
Cytokine (2024) Vol. 176, pp. 156532-156532
Closed Access | Times Cited: 3
The immunomodulatory ballet of tumour‐derived extracellular vesicles and neutrophils orchestrating the dynamic CD73/PD‐L1 pathway in cancer
Dominique S. Rubenich, Jordana L. Domagalski, Gabriela F. S. Gentil, et al.
Journal of Extracellular Vesicles (2024) Vol. 13, Iss. 7
Open Access | Times Cited: 3
Soluble immune checkpoint molecules: mechanism of formation, function, role in malignant neoplasms
Glazanova Tv, Irina Pavlovа, E. V. Kuzmich, et al.
Medical Immunology (Russia) (2025) Vol. 27, Iss. 1, pp. 21-34
Open Access
A colorimetric biosensor for the analysis of circulating PD-L1 with application to diagnose breast cancer
Yincheng Liu, Tianyu Zeng, Shuai Wu, et al.
Sensors and Actuators B Chemical (2025), pp. 137334-137334
Closed Access
Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease
Ayaka Hayashi, Hiroto Ishihara, Mayuko Kawabe, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Assessing the Clinical Relevance of Soluble PD-1 and PD-L1: A Multi-Cohort Study Across Diverse Tumor Types and Prognostic Implications
Nikolay E. Kushlinskii, О. В. Ковалева, Alexei Gratchev, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 500-500
Open Access
PD-L1 importance in malignancies comprehensive insights into the role of PD-L1 in malignancies: from molecular mechanisms to therapeutic opportunities
Mojdeh Soltani, Mohammad Abbaszadeh, Hamed Fouladseresht, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access
Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model
Rianne D.W. Vaes, Francesco Cortiula, Shaowen Lyu, et al.
Lung Cancer (2025), pp. 108541-108541
Open Access
Alternative Splicing in Lung Adenocarcinoma: From Bench to Bedside
Wenjie Luo, Mingjing Xu, Nathalie Wong, et al.
Cancers (2025) Vol. 17, Iss. 8, pp. 1329-1329
Open Access
Liquid biopsy for cancer immunotherapy: Biomarkers to predict and monitor response upon immune checkpoint blockade
Chae Yeon Son, Deborah Lee, Hyun Sung Park, et al.
Coordination Chemistry Reviews (2025) Vol. 539, pp. 216767-216767
Closed Access
N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1
Bar Kaufman, Muhammad Abu-Ahmad, Olga Radinsky, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Nanophotonic immunoarray with electrochemically roughened surfaces for handheld detection of secreted PD-L1 to predict immuno-oncology efficacy
Shuvashis Dey, Kevin M. Koo, Emtiaz Ahmed, et al.
Lab on a Chip (2023) Vol. 23, Iss. 15, pp. 3443-3452
Closed Access | Times Cited: 9
Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer
Koji Teramoto, Tomoyuki Igarashi, Yoko Kataoka, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 11, pp. 3755-3764
Open Access | Times Cited: 7
The tumor immune microenvironment in pancreatic cancer and its potential in the identification of immunotherapy biomarkers
Ryouichi Tsunedomi, Yoshitaro Shindo, Masao Nakajima, et al.
Expert Review of Molecular Diagnostics (2023) Vol. 23, Iss. 12, pp. 1121-1134
Closed Access | Times Cited: 7
Mechanisms of T cell evasion by Epstein-Barr virus and implications for tumor survival
Daniel Sausen, Miriam C. Poirier, Laura Spiers, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7

Scroll to top